PCSK9抑制剂在动脉粥样硬化性心血管疾病中的抗炎作用研究进展

Research progress in the anti-inflammatory effect of PCSK9 inhibitors in atherosclerotic cardiovascular disease

摘要: 高脂血症是动脉粥样硬化性心血管疾病（ASCVD）的重要危险因素，降脂治疗是ASCVD治疗的重要内容。近些年来，前蛋白转化酶枯草溶菌素 9（proprotein convertase subtilisin/kexintype9，PCSK9）抑制剂被证实具有强效的降低低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDL-C）的作用，并被多个降脂指南推荐作为降脂治疗的重要方法。随着研究的深入，PCSK9抑制剂除具有降低LDL-C作用外，还发挥一定程度的抗炎作用。本文从PCSK9参与炎症反应角度出发，对PCSK9抑制剂在ASCVD中的抗炎作用作一综述。

Abstract: Hyperlipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering therapy is an important part of ASCVD treatment. In recent years, PCSK9 inhibitors, proven to have potent LDL-C lowering effects, have been recommended by several guidelines as an important method for lipid-lowering therapy. With the deepening of research, PCSK9 inhibitors not only have the effect of lowering LDL-C, but also play a certain degree of anti-inflammatory effect. This article reviews the anti-inflammatory effect of PCSK9 inhibitors in ASCVD from the perspective of the involvement of PCSK9 in inflammatory responses.